Want to see CH:DOCM full AI Analyst Report?
DOCM Stock Chart & Stats
CHF10.36
-CHF0.03(-0.29%)
At close: 4:00 PM EDT
CHF10.36
-CHF0.03(-0.29%)
Day’s Range― - ―
52-Week RangeCHF3.92 - CHF11.25
Previous CloseN/A
Volume89.27K
Average Volume (3M)342.18K
Market Cap
CHF481.85M
Enterprise ValueCHF276.63
Total Cash (Recent Filing)CHF149.92M
Total Debt (Recent Filing)CHF288.64M
Price to Earnings (P/E)―
Beta1.32
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.60
Shares Outstanding54,000,000
10 Day Avg. Volume377,518
30 Day Avg. Volume342,178
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.75
Price to Sales (P/S)0.27
P/FCF Ratio-3.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF10.93Price Target Upside5.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.73
Revenue Forecast (FY)CHF1.24B
Bulls Say, Bears Say
Bulls Say
High‑margin Digital ServicesRapid 110% growth in digital services (TeleClinic + Retail Media) creates a scalable, high‑margin revenue stream that materially improves CM3. As take‑rate and media revenues scale, they can offset low‑margin Rx retailing and sustainably lift group margins over multiple quarters.
Large Customer & Platform ScaleServing ~11m active customers with improving order frequency and repeat rates builds durable lifetime value and cross‑sell potential. This scale supports lower unit marketing costs, higher retention, and better AOVs, underpinning structural revenue growth and margin expansion over 2–3 years.
Improved Liquidity & Lower LeverageA stronger balance sheet with CHF160m liquidity, reduced net debt and ~50% equity ratio provides a multi‑quarter runway to execute the turnaround plan, absorb restructuring costs, and reduces immediate refinancing pressure while management pursues EBITDA and FCF targets.
Bears Say
Severe Cash BurnPersistent negative operating and free cash flow materially depletes liquidity and forces reliance on external funding or asset sales. Continued cash burn constrains investment in logistics and growth initiatives and raises refinancing risk until FCF turns sustainably positive.
Large Adjusted EBITDA LossesSignificant FY2025 EBITDA losses undermine the company’s ability to become self‑funding; management targets breakeven in 2026 but execution risk, cost pressures and volatile Rx margins mean profitability could be delayed, prolonging cash strain.
Working‑Capital & Receivables IssuesMaterial working‑capital inefficiencies and receivables shortfalls tie up cash and reduce operational flexibility. Unless fixed, these structural issues will keep cash conversion weak, increase financing needs, and impair the durability of any margin improvements.
DOCM FAQ
What was DocMorris AG’s price range in the past 12 months?
DocMorris AG lowest stock price was CHF3.92 and its highest was CHF11.25 in the past 12 months.
What is DocMorris AG’s market cap?
DocMorris AG’s market cap is CHF481.85M.
When is DocMorris AG’s upcoming earnings report date?
DocMorris AG’s upcoming earnings report date is Aug 19, 2026 which is in 4 days.
How were DocMorris AG’s earnings last quarter?
Currently, no data Available
Is DocMorris AG overvalued?
According to Wall Street analysts DocMorris AG’s price is currently Undervalued.
Does DocMorris AG pay dividends?
DocMorris AG does not currently pay dividends.
What is DocMorris AG’s EPS estimate?
DocMorris AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does DocMorris AG have?
DocMorris AG has 54,000,000 shares outstanding.
What happened to DocMorris AG’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of DocMorris AG?
Currently, no hedge funds are holding shares in CH:DOCM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
DocMorris AG
DocMorris AG is a key player in the pharmaceutical sector, focusing on both online pharmacy services and the wholesale supply of medical and pharmaceutical goods. The company provides a comprehensive selection of items, including prescription and over-the-counter medications, health and wellness products, beauty and personal care lines, dietary supplements, pain relief remedies, and emergency first aid supplies. Furthermore, it offers specialized medication management support. In addition to its significant digital footprint, DocMorris AG also operates traditional brick-and-mortar pharmacy locations. Its commercial activities extend across Switzerland and into various international territories, serving medical practitioners, other online pharmaceutical distributors, and individual consumers directly. Notable brands within its portfolio include Zur Rose, PromoFarma, TeleClinic, and DocMorris. Established in 1993 and based in Frauenfeld, Switzerland, the company adopted its current name, DocMorris AG, in May 2023, having previously been known as Zur Rose Group AG.
DOCM Stock 12 Month Forecast
Average Price Target
CHF10.93
▲(5.45% Upside)
Technical Analysis
Idorsia Ltd
―
Santhera Pharmaceuticals Holding
―
Galenica AG
―
Galderma Group AG
―
medmix AG
―